儿科肿瘤中基于配对肿瘤-胚系测序的胚系病理性变异的家族回忆和反应。
Family Recall of and Response to Germline Pathologic Variants Found on Paired Tumor-Germline Sequencing in Pediatric Oncology.
机构信息
Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
出版信息
JCO Precis Oncol. 2024 Mar;8:e2300539. doi: 10.1200/PO.23.00539.
PURPOSE
Paired tumor-germline sequencing can identify somatic variants for targeted therapy and germline pathogenic variants (GPVs) causative of hereditary cancer/tumor predisposition syndromes. It is unknown how patients/families in pediatric oncology use information about an identified GPV. We assessed recall of germline results and actions taken on the basis of findings.
METHODS
We completed phone surveys with patients (and/or their parent) with GPVs identified via a single academic medical center's paired tumor-germline sequencing study. Seven hundred forty pediatric (aged 0-25 years) oncology patients were enrolled in this sequencing study between May 2012 and August 2021. Ninety-six participants (13.0%) had at least one GPV identified and were therefore eligible for this survey. The parent/guardian (for patients younger than 18 years or deceased patients) or patients themselves (if 18 years or older) were contacted. Survey topics included germline result recall, experience with genetic counseling, changes to patient's cancer treatment/screening, sharing of results with family members, and lifestyle changes.
RESULTS
Fifty-three surveys (response rate, 55.2%) were completed between October 2021 and June 2022. Thirty-seven (69.8%) respondents correctly recalled the identified GPV. Discussing results with a genetic counselor ( = .0001), having a GPV related to the cancer/tumor diagnosis ( = .002), and non-Hispanic White race/ethnicity ( = .02) were associated with accurate recall. Twenty-five respondents (47.2%) reported a change in the child's cancer treatment and/or screening recommendations, 17 respondents (32.1%) made a lifestyle change on the basis of the results, and 44 respondents (83.0%) shared results with at least one family member.
CONCLUSION
While most respondents remembered that a GPV was identified in the patient, some did not recall having a GPV found, and others recalled germline findings incorrectly. Future work may determine patient/family preferences for timing/method of result return to optimize patient recall and use of germline results.
目的
配对的肿瘤-种系测序可以识别针对靶向治疗的体细胞变异和导致遗传性癌症/肿瘤易感性综合征的种系致病性变异(GPV)。目前尚不清楚儿科肿瘤患者/家庭如何使用已确定的 GPV 信息。我们评估了基于发现结果的种系结果召回和采取的行动。
方法
我们对通过单一学术医疗中心的配对肿瘤-种系测序研究确定 GPV 的患者(和/或其父母)进行了电话调查。2012 年 5 月至 2021 年 8 月,共有 740 名儿科(0-25 岁)肿瘤患者参加了这项测序研究。96 名参与者(13.0%)至少有一个 GPV 被确定,因此有资格参加这项调查。父母/监护人(对于 18 岁以下的患者或已故患者)或患者本人(如果年满 18 岁)接受了调查。调查主题包括种系结果召回、遗传咨询经验、患者癌症治疗/筛查的变化、结果与家庭成员的共享以及生活方式的改变。
结果
2021 年 10 月至 2022 年 6 月期间完成了 53 份调查(回复率为 55.2%)。37 名(69.8%)受访者正确回忆起已确定的 GPV。与遗传咨询师讨论结果(P=0.0001)、GPV 与癌症/肿瘤诊断相关(P=0.002)和非西班牙裔白人种族/民族(P=0.02)与准确回忆相关。25 名受访者(47.2%)报告了儿童癌症治疗和/或筛查建议的改变,17 名受访者(32.1%)根据结果改变了生活方式,44 名受访者(83.0%)与至少一名家庭成员分享了结果。
结论
虽然大多数受访者记得在患者中确定了 GPV,但有些受访者没有回忆起发现了 GPV,还有些受访者错误地回忆了种系发现。未来的工作可能会确定患者/家庭对结果返回时间/方法的偏好,以优化患者的回忆和种系结果的使用。